LEADING THE WAY IN CLINICAL RESEARCH

OUR JOURNEY OF EXCELLENCE

TABLE OF CONTENTS

TABLE OF CONTENTS

MESSAGE FROM THE CEO

HELLO & WELCOME,

As the CEO overseeing Revival, Revive and NHO Revive I am honored to present this brag book that encapsulates our shared journey in redefining clinical research and patient care, one clinical trial at a time.

Each of these organizations, while operating as distinct entities, contributes uniquely to our overarching mission and embodies our collective tagline.

> ***Redefining Clinical Research & Patient Care, One Clinical Trial At A Time.***

This compilation is not just a showcase of our achievements but a testament to the synergistic power of all our organizations. Revival, known for its innovative approaches; Revive, with its pioneering spirit; excelling in operational excellence; and NHO Revive focusing on delivering exceptional care – together, we have expanded our footprint across new sites in the U.S., driven by a shared commitment to excellence in clinical research.

The testimonials featured herein speak volumes of the trust placed in us by the Sponsors and the exceptional dedication of our teams across all three entities. They illustrate our collaborative success and the individual contributions that make it possible.

As we look to the future, our collective vision remains focused on leading the way in clinical research, constantly evolving to meet the challenges of this dynamic field. We are excited about the opportunities that lie ahead for our organizations.

Thank you for being an integral part of our journey and for joining us as we continue to make strides in clinical research and patient care.

Sincerely,
Mazhar Jaffry

COMPANY OVERVIEW

Revival Research Institute, LLC is an integrated research site network that caters to a diverse patient population and is committed to providing clean data and quality care to patients. Our focus is on optimizing and streamlining processes through the integration of innovative technologies, aiming to minimize risks and errors in scientific data while conducting efficient trials for our sponsors.

We prioritize tailoring our strategies to meet the unique requirements of each clinical trial, ensuring strict compliance with study protocols and timely regulatory submissions. Central to our approach is transparent communication, which fosters open channels for all stakeholders, especially concerning patient safety and data integrity.



Building Strong Partnerships for Better Clinical Trial Outcomes

We emphasize fostering strong partnerships with healthcare providers and research institutions, allowing us to expand our reach and access to diverse patient populations. This collaboration drives better trial outcomes and contributes to advancing clinical research.

Driving Efficiency & Innovation in Patient-Centric Clinical Research

Our reliable and predictable processes enable us to meet critical milestones faster than the industry average. We leverage real-world insights and research expertise to develop patient-centric solutions in clinical research that can be effectively implemented on a larger scale.

OUR PROMISES

FAST STUDY START-UP

As a clinical research site network, we streamline study start-up to activate sites quickly and begin enrollment without delays. By accelerating contracts, ethics approvals, and site initiations, our experienced team shortens timelines and ensures trial readiness, helping sponsors meet deadlines and deliver therapies to patients faster.

HIGHEST PATIENT RECRUITMENT

Our approach to patient recruitment is strategic and effective, ensuring high enrollment rates and diverse participant pools. By employing targeted recruitment strategies and engaging patients through multiple channels, we consistently meet our enrollment targets on time. Our efforts also focus on retention, ensuring participants remain engaged throughout the study duration.

QUERY-FREE DATA

At Revival's Site Network, we pride ourselves on providing query-free data ensuring accuracy, precision and compliance with our regulatory standards. Our data undergoes meticulous review and verification processes, guaranteeing that it meets the highest quality standards. This commitment to excellence means fewer queries, reduced delays, and a smoother path to approval for our clients.

MISSION

Revival's Site Network aims to transform healthcare with cutting-edge research studies, focusing on safety, innovation, and quality. Our mission is to ethically advance medicine by conducting rigorous and groundbreaking clinical trials. As a trusted and reliable partner in healthcare, we strive to improve lives by ensuring the highest standards in our clinical trials, fostering a culture of excellence, and pushing the boundaries of medical knowledge. We are committed to collaborating with healthcare professionals, patients, and stakeholders to deliver impactful solutions and make a lasting difference in the field of clinical research.

VISION

Revival's Site Network envisions transforming healthcare by collaborating with top pharmaceuticals, leveraging our experts' knowledge to democratize clinical trials and fast-track the accessibility of life-changing therapies. By fostering strong partnerships with leading industry players and utilizing the expertise of our dedicated team, we aim to streamline the clinical trial process, making it more inclusive and efficient. Our goal is to ensure that groundbreaking treatments and therapies are available to all who need them, regardless of their background or circumstances. Through our approach and commitment to excellence, we are changing the landscape of clinical research and improving health outcomes on a global scale.

CORE VALUES

As a clinical research site network, it's important to establish and uphold core values that reflect our commitment to conducting ethical, high-quality, and patient-centric research. Here are some core values that we focus on:

Integrity & Respect: Uphold the highest levels of integrity in all our interactions, whether it's with participants, sponsors, regulatory agencies, or the public.

Ethical Conduct: Uphold the highest ethical standards in all aspects of research, including informed consent, data collection, analysis, and reporting. Ensure that the trial adheres to all relevant regulations and guidelines.

Patient-Centered Approach: Prioritize the well-being and safety of research participants. Ensure that their rights and dignity are respected throughout the research process. Provide clear and understandable information to participants about the research process, potential risks and benefits, and their rights, empowering them to make informed decisions.

Compliance & Quality Assurance: Adhere to all applicable laws, regulations, and industry standards related to clinical research, including Good Clinical Practice (GCP) guidelines.

Transparency & Accountability: Being open and transparent in all communications, including disclosing conflicts of interest, and providing clear information to participants and the public. Also, taking responsibility for our actions and decisions and holding ourselves accountable for the quality and ethical conduct of research.

Collaboration: Foster collaboration and teamwork among researchers, healthcare professionals, and stakeholders to advance the field of clinical research.

Innovation: Embrace innovation and stay up-to-date with the latest advancements in research methodologies, technologies, and therapies to improve the quality and efficiency of research.

These core values help guide our company's mission and actions, and they are essential for building trust with participants, sponsors, and the broader healthcare community. They also contribute to the credibility and success of our research endeavors.

THE STORY OF REVIVAL, REVIVE AND NHO REVIVE: REDEFINING RESEARCH AND PATIENT CARE

In the world of clinical research, where precision and compassion intersect, our three sister organizations—Revive, Revival, and NHO Revive —emerged as beacons of innovation and excellence. Our journey is a testament to the power of collaboration, dedication, and a shared vision.

Driven by a deep understanding of patient needs and a commitment to improving outcomes, our approach is inherently patient-centric. Every initiative we undertake revolves around enhancing the patient's experience, setting us apart in our field. Our focus on innovation and empathy guides every decision we make, ensuring that we remain at the forefront of advancements in healthcare.

Participating in the esteemed WCG MAGI Clinical Research Conference – 2024 was a significant achievement for Revival's Site Network.

With a steadfast focus on innovative therapies, we are actively reshaping the future of healthcare, one patient and one clinical trial at a time. We are confident that our participation in the conference has made a positive impact, inspiring fellow professionals to join us in our mission to improve the lives of millions with compassion at the forefront of all our endeavors.

We are now looking forward to inaugurating new sites, exciting studies, and upcoming projects in the future.

This prestigious event provided us with a platform to contribute to the advancement of healthcare, aligning perfectly with our mission to revolutionize the field and enhance patient lives through innovative technologies. Participating in the esteemed WCG MAGI Clinical Research Conference – 2024 was a significant achievement for Revival's Site Network.

REVIVING QUALITY OF LIVES ONE CLINICAL TRIAL AT A TIME

As a clinical research site network, our mission is clear, to transform healthcare through clinical studies that prioritize safety, innovation, and quality. With a steadfast commitment to advancing medicine ethically, we set out to improve lives and become a trusted partner in healthcare.

Central to our mission is the cultivation of trust and collaboration within the research community. We recognize that true progress is achieved through collective effort and shared vision. As such, we strive to foster meaningful partnerships with clinicians, researchers, pharmaceuticals, and regulatory bodies. Together, we leverage our collective expertise and resources to address unmet medical needs and drive innovation forward.

However, our mission extends far beyond the confines of research sites. It encompasses a broader commitment to societal impact and patient advocacy. We recognize that behind every data point lies a human story, and we approach our work with a deep sense of empathy and compassion. Our dedication to patient-centric care is evident in every interaction, from the informed consent process to post-trial follow-up.

STORIES OF ACHIEVEMENT

The journey of Revival, Revive and NHO Revive is filled with stories of achievement. From the successful completion of the "ECHO-004 Kosmos Trio and Ejection Fraction Pivotal Study" by Revival, which saved EchoNous's product rollout, to the exceptional dedication of teams working tirelessly to meet tight deadlines and achieve remarkable results—these stories reflect the heart and soul of these organizations.

These triumphs are not just milestones; they are testaments to the resilience, ingenuity, and dedication of the teams behind them. Whether it's overcoming regulatory hurdles, recruiting challenging patient populations, or implementing complex protocols, Revival, Revive and NHO Revive have consistently demonstrated their ability to turn challenges into victories. Their stories of triumph inspire others in the industry and reaffirm their commitment to excellence.

GCSA CERTIFICATION AS A BENCHMARK OF CLINICAL EXCELLENCE

With great pride and excitement, we celebrate a significant milestone in our journey: the prestigious certification by the Global Quality Standard for Clinical Research Sites (GCSA). This achievement marks a pivotal moment in propelling our research efforts forward and reaffirms our unwavering commitment to maintaining the highest global standards in operational processes for clinical research.

We are thrilled to announce our attainment of GCSA certification. This achievement reflects our unwavering dedication to advancing healthcare and maintaining the highest standards of quality and integrity in clinical research. Moving forward, we remain committed to driving innovation and making meaningful contributions to the field.

Nicole Stiff
Corporate Operations & Business Development Manager

Several pivotal factors have contributed to our successful attainment of the GCSA Certification. Firstly, the institute prioritizes rigorous data quality, employing robust processes to ensure the accuracy and integrity of clinical trial data, thereby safeguarding the validity and reliability of research findings. Secondly, we have a team of highly trained and experienced research professionals, ensuring that every facet of research operations is executed with the utmost expertise and proficiency. Thirdly, our team is committed to continuous improvement, continually identifying areas for enhancement to optimize site performance and bolster the efficiency of its research endeavors.

OUR SITE NETWORK SETUP IN THE UNITED STATES

Revival's Site Network is actively working towards expanding and increasing access to clinical research in various locations across the United States. Our primary objective is to make clinical trials readily available to the local population of diverse communities. To achieve this, we have formed strong collaborations with experienced and diverse healthcare professionals, as well as organizations including Accountable Care Organizations (ACOs) and Healthcare Networks that provide us with top-notch Principal Investigators and patient populations in need of clinical trials.

Through these partnerships, we strive to ensure that our clinical trials are conducted with the utmost care and precision, delivering valuable insights and potential therapies for the benefit of the communities we serve in the United States.

Our PI's work as independent contractors

30+ Principal Investigators & 27+ Sub-Investigators throughout the United States

Over **25+ sites** interspersed throughout the United States
Michigan, Texas, Nebraska, Georgia, North Carolina & Illinois.



SUCCESS IN MOTION: DEARBORN TEAM'S ACHIEVEMENT

EmitBio RD-X19 | Dr. Saad | Site 315 | Congratulations!

Dear Team,

While delayed, I could not let another minute pass without me congratulating the Dearborn team on the first randomization!

Hard work pays off… now press repeat!

As always, please contact us if you need anything.
Your success is ours!"

Marla Mills-Wilson
Director, Clinical Operations

EmitBio™

FROM CHALLENGE TO SUCCESS: ECHONOUS' JOURNEY WITH OUR NETWORK

Dear Revival Team,

This letter is to set forth our company's gratitude to the excellent work of the Revival team located in Dearborn, Michigan, in their completion of our company's study entitled "ECHO-004 KOSMOS TRIO AND EJECTION FRACTION PIVOTAL STUDY." The FDA required this study be completed in order to grant us clearance to continue to sell our flagship device, the Kosmos System, an AI-assisted EKG/ultrasound machine.

By way of background, in the summer of 2023, EchoNous was in the unfortunate position of losing its study site for the ECHO-004 Study. A tight FDA deadline loomed in November to submit the finalized results. EchoNous contacted Revival to assist us in our predicament and from there we were consistently met with a "can do" attitude of the Revival team, who quickly jumped in with "all hands-on deck" to act as our study site.

The ECHO-004 Study was no small task. It involved the training of Revival staff and their use of our Kosmos device to achieve specific cardiac views. Revival was very aggressive in pulling together the necessary people and organizing the logistics to make our study happen in the short window of time available. Revival even finished ahead of schedule!

Throughout the study, Revival was professional, courteous, organized, and communicative. They worked long hours and were tireless in their dedication to finishing our study. Without the Revival team's help, EchoNous never would have met its FDA timeline, which in turn would have caused harm to EchoNous's product rollout and sales.

We at EchoNous are so appreciative to the Revival team for all that they have done to make our study a success.

Thank you!

Rebecca L Penn
R.P, General Counsel

EchoNous

BAYER'S EXPERIENCE WITH US

Dear Team,

The US Team at Bayer would like to extend a heartfelt thank you to your site for the hard work and dedication in contributing to Hispanic Patient Inclusion Diversity Randomizations over the past week! Your hard work is noticed and recognized!

THANK YOU!

OCEANIC- AF Team

> ***Extending a heartfelt thank you to your site for the hard work and dedication in contributing Hispanic patient inclusion Diversity Randomizations***

OUR SITE IN MICHIGAN AMONG THE TOP ENROLLERS

BIOFOURMIS

NOVEMBER 2023 AIM-POWER CLINICAL TRIAL

TOP ENROLLING SITES

CURRENT NOVEMBER TOP ENROLLING SITE

as of November 6th, 2023

Dr. Shafiq - *Revival Research*

CONGRATULATIONS TO THE TWO OCTOBER CHALLENGE WINNERS

Dr. Ahsan - *University Medical Center*
Dr. Sethi - *Cardiac Solutions*

CUMULATIVE TOP ENROLLING SITES

as of November 6th, 2023

Dr. Lam - *Medstar Washington*
Dr. Bennett - *Jackson Heart*
Dr. Syed - *Austin Heart*
Dr. Ahsan - *University Medical Center*
Dr. Khetpal - *Heart and Medical Center*
Dr. Shafiq - *Revival Research*

Site Distribution

Map pins indicate active and soon-to-be active sites.

Biofourmis



DR. SHAFIQ'S SITE WITH TOP ENROLLMENT OF 7 SUBJECTS FOR THE MONTH OF NOVEMBER. WAY TO GO!

Our independently owned site network spans across the United States, with each site contributing a distinctive role in every aspect of clinical research. Each location operates with its own expertise and specialized focus, ensuring a tailored approach to meet diverse research needs. By leveraging the unique strengths of each site, we offer a comprehensive and versatile network that enhances the effectiveness and efficiency of clinical trials. This collaborative framework allows us to provide high-quality, customized solutions that address the specific requirements of each study, driving innovation and success across the entire network.

WHAT SPONSORS HAVE TO SAY ABOUT OUR SITE

I wanted to provide some feedback about sites 7806 and 7823. I found both sites were run well and would name them both as some of my top sites in this study. I appreciated the prompt response times and follow-up and never really had to worry about whether a query would be answered or an issue taken care of etc. It truly was a pleasure working with you both and I would be happy to refer you for future studies if Parexel does ask my opinion.

Thanks!

"I appreciated the prompt response times and follow-up and never really had to worry about whether a query would be answered or an issue taken care of"

Louis Noble, Senior Clinical Research Associate

parexel®


REVIVAL
RESEARCH INSTITUTE, LLC
REVIVAL
RESEARCH INSTITUTE, LLC
REVIVAL
RESEARCH INSTITUTE, LLC

OUR PARTNERS IN PROGRESS

No great journey is undertaken alone. Our success story is deeply intertwined with the support and collaboration of our esteemed sponsors. These visionary partners have been instrumental in elevating healthcare to remarkable heights.

They have served as strategic partners throughout, offering invaluable expertise, resources, and unwavering encouragement. Their contributions have enriched our endeavors, infusing them with wisdom and insight that have been instrumental in our pursuit of excellence.

As we reflect on our journey thus far, we do so with profound gratitude for the unwavering support of our sponsors. Their partnership has been instrumental in our success, and we remain committed to advancing our shared goals together, as partners in progress.

WHAT WE OFFER TO SPONSORS?

At Revival's Site Network, our commitment is to provide outstanding results and unparalleled support for our sponsors throughout every stage of the clinical trial process. Our dedication to excellence and rigorous adherence to regulatory standards ensure that we deliver the highest quality outcomes from Phase I through Phase IV.

Expertise and Regulatory Adherence

Our team brings a wealth of expertise and in-depth knowledge to each clinical trial. We are dedicated to maintaining the highest standards of regulatory compliance, ensuring that every aspect of the trial meets or exceeds industry requirements. Our meticulous approach to regulatory documentation and processes guarantees that your study adheres to all necessary guidelines, minimizing risks and ensuring smooth progress.

Streamlined Processes

Our streamlined processes are designed to facilitate efficient trial execution, from initial planning through to final analysis. We prioritize effective communication and coordination, ensuring that each phase of the trial is executed seamlessly. Our efficient enrollment strategies, rapid study startup timelines, and effective patient recruitment methodologies are key factors in our success.

EXCEPTIONAL SUBJECT RETENTION

At Revival Research Institute, our commitment to exceptional subject retention is demonstrated by our impressive 88% study completion rate. This high level of retention reflects our comprehensive approach to participant support and engagement throughout the trial process.

PROVEN TRACK RECORD

With a strong track record of successful trials that have made a significant impact on the medical community, Revival's Site Network has established itself as a trusted partner in clinical research. Our history of positive outcomes and satisfied sponsors underscores our ability to deliver results that advance medical science and contribute to the development of life-saving therapeutics.

OUR TRACK RECORD

We strive for trial operational excellence and highly focused recruiting for clinical trials in Michigan, Illinois, Texas, Nebraska, Georgia, and North Carolina. Here's an insight into our journey so far. Here are our metrics.

10K+	120+	25+
Patients Enrolled Successfully	Active Studies	Research Sites
200+	12+	30+
Dedicated Employees	Therapeutic Areas	Principal Investigators

BENEFITS OF JOINING REVIVAL'S INVESTIGATOR'S NETWORK: OUR OFFER TO PHYSICIANS

Revival's Site Network partners with primary care physicians and specialists across the United States, including North Carolina, Georgia, Illinois, Nebraska, Michigan and Texas to enhance the solutions we offer to our physicians and increase patient access to advanced care and novel therapies.

BE A LEADER IN CLINICAL RESEARCH

At the core of our patient-centered clinical trials is a dedicated team of experienced clinical research physicians, including principal and sub-investigators, and senior medical experts. Your role as a Principal Investigator will be vital in developing new pharmaceuticals and positioning research as a viable care option for your patients.

SHAPE THE FUTURE OF MEDICINE

As an Investigator, you have a unique chance to shape the future of medicine through specialized trials aligned with your research interests. Whether your passion lies in patient care or driving medical advancements, you have the potential to contribute to the next major breakthrough.

FOCUS ON PATIENT CARE

Working as a clinical research physician allows you to minimize administrative tasks, cut costs, and enhance the quality of clinical trials. We want you to focus on what you do best, helping patients and offering research as an added care option.

COLLABORATE WITH EXPERTS

Collaborating with Revival's Site Network offers you the chance to work with numerous pharmaceutical and biotechnology organizations while gaining exposure to a wide range of research projects.

It's been a pleasure working with the Revival Research Institute, LLC team for the past few months now. Everyone on their team has been a tremendous asset to this study & the level of collaboration is impeccable. Their team is very responsive to questions, and always took the time to answer each one thoroughly. Their diligence, hard work, and expertise in conducting clinical trials shines!

Marsha Teodori, Clinical Trial Educator

IQVIA™

REVIVAL'S COMMITMENT TO DIVERSITY IN CLINICAL TRIALS

DIVERSITY & INCLUSIVITY

With 33% of our participants coming from marginalized backgrounds, Revival's Site Network stands at the forefront of promoting diversity in clinical trials. This commitment ensures that our research findings are relevant and applicable to a wide range of populations, ultimately leading to more inclusive and equitable healthcare solutions.

ACCESSIBILITY

We are committed to making clinical trials accessible to underrepresented communities, particularly in regions that have historically been marginalized in research. Our strategically located sites ensure that individuals from these areas can participate in and benefit from leading-edge medical studies.

MULTI-LINGUAL STAFF

To support our diverse participant base, we employ a team of multilingual staff proficient in various languages. This enables us to communicate effectively with participants from different linguistic backgrounds, ensuring they feel comfortable and well-informed throughout the trial process.

OUR COMMITMENT TO GROWTH

INAUGURATION OF ALL-HANDS MEETING

A First-of-its-Kind Learning Experience at Revival

The quarterly All-Hands Meeting series, inaugurated in 2023, marked a significant milestone in Revival's commitment to employee development. This initiative was designed to enhance the knowledge and skills of our internal staff, setting a strong foundation for continuous learning and growth.The success of the first session, which left employees with sharpened abilities and a deeper understanding of the institute's strategic direction, demonstrated the value of this initiative.

Revival's Site Network places immense value on the personal growth and development of its employees. By cultivating a culture that encourages ownership and pride, Revival ensures that every team member feels motivated and empowered. This focus on personal development is not just an organizational goal but a core belief that the success of Revival is deeply linked to the well-being and professional advancement of its employees. We are dedicated to helping our staff identify their strengths, fostering an environment where each can thrive and contribute meaningfully to our collective mission.

Looking ahead, Revival plans to continue these meetings into the future, with each session building upon the last to ensure our team remains at the forefront of the industry.
The All-Hands Meetings are not just about professional development; they are also a key component of our broader mission to empower our employees. By providing them with the tools and knowledge they need to excel, we are investing in the future of our team and the organization.

CULTIVATING LEADERSHIP AND GROWTH: DEBUT OF ANNUAL LEADERSHIP MEETING

On January 12, 2024, Revival's Site Network launched its inaugural Leadership Meeting, marking the beginning of a new annual tradition. This significant event celebrated the staff's outstanding achievements in clinical trials, compliance, and recruitment, while also setting ambitious goals for the year ahead.

The Leadership Meeting provided a comprehensive review of the company's accomplishments and outlined key objectives for the coming year. It highlighted Revival's commitment to personal development and leadership growth, offering valuable insights and strategies for enhancing individual and collective success.

The core focus of the meeting was personal development. We at Revival are dedicated to nurturing each team member's potential, and the event emphasized the importance of self-improvement, skill development, and proactive career management. Through engaging in workshops and discussions, employees gained practical examples to enhance their leadership capabilities and embrace opportunities for growth.

In alignment with Revival's philosophy, the meeting underscored the goal of making every team member a leader. By fostering a culture of collaboration, accountability, and innovation, Revival empowers staff to lead from their positions, driving both individual and organizational success.

The Leadership Meeting 2024 set a collaborative tone for the year, encouraging all members to align their personal goals with the company's mission. This event is set to become an annual tradition, reinforcing the importance of teamwork and shared aspirations as Revival continues to build a dynamic and forward-thinking organization.

In summary, the Leadership Meeting was a landmark event that not only celebrated past successes but also laid a strong foundation for future achievements. By focusing on personal development and leadership, we at Revival, are committed to fostering a culture where every individual can thrive and contribute to the company's ongoing success.

BUILDING STRONG PARTNERSHIPS: COMMITTED TO SUPPORT & PROFESSIONALISM

At Revival Research Institute, we pride ourselves on fostering a supportive environment where every team member is heard, seen and valued. We are dedicated to delivering exceptional results through our commitment to excellence and professionalism. Our team's hard work and expertise are reflected in the positive feedback we receive from our partners and sponsors. Each testimonial highlights the outstanding contributions and high standards that define our approach to clinical research.

Exemplary Diligence & Efficiency in Clinical Research

We are dedicated to upholding the highest standards in clinical research through meticulous attention to detail, deep expertise and commitment to detail. Our team's ability to deliver outstanding results while maintaining efficient processes is a testament to our core values.

TESTIMONIAL

I would say that I have been working very closely with Navya Kamath and I can say that she has been truly great to work with on the Amgen Atopic Dermatitis Studies. She has been diligent, whilst circumspectly navigating every aspect of the studies, knowledgeable and understanding of research processes, and policies, and easy to work with.

As a whole, I believe your site overall has exhibited above-average remarks regarding recruitment, data entry, quality, and responsiveness. To give some perspective on your site overall with the two current Amgen atopic dermatitis studies:

- For the 20210143 study, your site's overall % of data entry less than or equal to 7 days is 87.5% and your overall % of queries resolved within less than or equal to 7 days is 72.4%, excluding all of December.
- For the 20210146 study, your site's overall % of data entry less than or equal to 7 days is 95.3% and your overall % of queries resolved within less than or equal to 7 days is 98.2%. Excluding all of December.

Great job! It is always a pleasure to work with your site.

Megi Gojka,
Clinical Site Manager

AMGEN

EXCEPTIONAL SUPPORT & EXPERTISE

At Revival Research Institute, our commitment goes beyond conducting clinical trials — it's about providing unwavering support, expertise, and a collaborative spirit at every stage. From high enrollment numbers to seamless close-out procedures, our team's dedication to overcoming challenges and achieving excellence is evident in every study we undertake.

The following testimonials showcases the exceptional care and professionalism our staff brings to every partnership:

"

I would like to thank you and your entire team for your hard work and support on the CDX0159-04 study. Not only did you enroll a high number of subjects, but your staff is very supportive and responsive.

I especially want to thank everyone for your expertise and diligence during the close-out phase of this study, which was the phase that I was directly involved with.

I also, especially would like to thank Ria Abraham for the exceptional job she did. I contacted her for many follow-up items, and she always responded quickly and provided the information we needed. Even when she was busy, she found time to support us. I could not have done the close-out visit and final close-out tasks without her! Navya Kamath was also exceptional. She did a great job answering all our questions and helping us with this study. Rian and Navya are both very professional and team players. Please thank them both.

This study was a bit complicated when it came to IP blinding. Thank you, Yamini, and the rest of the Revival staff for working closely with me to get an adequate IP reconciliation. The other departments were great as well. The Regulatory team did such a nice job supporting us.

Your staff always provided us with such a warm welcome and supported us during the study visits. The working area at your site is very nice for our CRAs.

Thank you for everything and hope to work with you all again soon!

Debra Barrette
Clinical Research Associate

Celldex therapeutics

"

I have worked closely with both Manali and Navya on the INCYTE 206 & 319 studies, and man-o-man has it been a real pleasure to work with both of them! They have both been a Monitor's dream/ideal Study Coordinators to work with. Manali and Navya are extremely knowledgeable about the protocols, study procedures, and how to use the study platforms/devices. If there is ever an issue or error, they are proactive in letting me know, and finding solutions/corrective actions immediately, rather than me having to discover the errors when I come on-site. They are extremely receptive to any feedback/suggestions I may have and make any necessary corrections on time.

I can't speak for the 206 study since I wasn't with your site at the start of it, but for the 319 study, Manali, Navya, and you have helped tremendously in working out the study kinks within the IRT, eDiaries, and EDC. I know you all blazed the trail in enrollment for the 319 study, so you were the first to test-run and find out when systems weren't working like they were supposed to. There were definitely hiccups with randomizing participants in IRT, eDiaries syncing/populating, and excessive query issuing in EDC. You all had the expertise and knowledge to know when things weren't working right, and always took the right actions by contacting me or the study team to inform us of the issues and find out the next best steps forward. I want to thank you all so much because I know it's never fun being the first to blaze the way, but it's because of your hard work through these starting hiccups that the study is now running smoother and more efficiently! You all were always so helpful and patient and never complained when working through those early study days.

Any time I email or call Manali or Navya, I always get a response within 24-48hours. No part of my email goes unanswered. I truly appreciate their attention to detail and diligent follow-up with patients and my own ad-hoc requests.

You all have also SMASHED it out of the park with recruitment! Your site is one of the highest enrollers for both the 206 and 319 studies, and you still manage to have quality data and timely EDC entry. I do not know how you all do it, but it is truly top-tier work! Your source is very detailed and captures all necessary procedures. If I put a comment in RealTime, it is always answered/resolved by the next time I come on-site. I never have to pester Manali or Navya about outstanding open queries, they always stay on top of them, and resolve them within the study agreed timelines.

Manali & Navya are both incredibly hard workers, but they are also just great people and a joy to be around and interact with! They always greet me with a smile and have a positive attitude.

I truly love coming to and working with your site! I hope to have many more studies with you all in the continued future.

Thanks!

Incyte

Rachel Wank
Senior Clinical Research Associate, Site Management

Revival and Revive Research Teams,

THANK YOU!!! I wanted to send a message to let you know what great research teams you have. I have only been covering Michigan for about 3 years (I was on the East Coast for over 10 years and Southeast for another 5). Your team is easy to work with, quick to respond to emails, phone calls, and above all, you are a dedicated and cohesive team. I very much appreciate the early mornings and late-night hours your team has put into finding appropriate COVID-19 patients for PYAB. Your team communicates well with each other, and without your dedicated staff and support, we would not have been able to complete addenda 3.0 today. I just wanted to take a few minutes to acknowledge everyone who has worked so hard over the last few weeks to deliver the addenda. This work is so important to support the current EUA for our antibodies and to help patients in need have treatment options through this pandemic. I am truly grateful to all of you! Thanks again for all you do every day to support research and advance COVID-19 therapies.

Amy Jenkins, MSN, NP

Lilly

EXCEPTIONAL DEDICATION & INCLUSIVE RESEARCH PRACTICES

At Revival we aim to achieve the highest standards in clinical research while ensuring diverse patient population. Our dedication to quality, timely data management and inclusivity is often recognized by our partners.

> Dr. Andrew Owens, MD, FAC, FHRS, Principal Investigator & clinical research study staff are conducting Bayer's OCEANIC atrial fibrillation clinical trial for the prevention of stroke or systemic embolism. The study is one of the largest Phase III clinical trials Bayer has underway. The clinical trial presently has 102 sites open to enrollment in the United States. Dr. Owens's site is the 6th highest enroller, with clean data and exceptionally rapid timelines for EDC data entry. As a senior clinical research associate, it is truly a privilege to be assigned to this remarkable site. I've worked in clinical trials since 2001 and have not been impressed with a site to such a magnitude. The first onsite visit was the site initiation (SIV). Walking into the site, I was instantly awe-struck by the décor of the practice/research site. Ms. Naila Aslam, the CRC warmly invited me to the impressive conference room where the study team was present & SIV took place. I've conducted hundreds of SIVs, and Dr. Owens's trial site has been the zenith. The study site staff are intelligent, engaged & gracious. Despite Dr. Owens's busy practice schedule, he carved out time for the SIV and illustrated interest & excitement for the study. After deemed "ready to enroll" by Bayer, the site hit the ground running.

Ms. Naila Aslam, a heartfelt thank you to your site for the hard work and dedication in contributing Hispanic patient inclusion Diversity Randomization. Dr. Andrew Owens, the PI & the clinical research study staff are conducting Bayer's OCEANIC atrial fibrillation clinical trial for the prevention of stroke or systemic embolism. The study is one of the largest Phase III clinical trials Bayer has underway. Ms. Naila Aslam, Lead Clinical Research Coordinator has exemplified brilliance in the challenging & stressful role of coordinating the study. She has a "can do" attitude, is inquisitive, & her positive nature is inspiring. Naila is visibly dedicated & striving for excellence.

Dana Nelson
Senior Clinical Research Associate

“I wanted to reach out to thank you and your site team for screening 2 subjects after only 11 days of being active on the DPN trial! The average time for a site to screen after joining has been 43 days. Your enthusiasm and commitment are truly appreciated!”

Tracy Newbold
Clinical Operations Lead

Lexicon pharmaceuticals

PATIENT-CENTRIC COMMITMENT & PROACTIVE RECRUITMENT

"Ayesha, Latoya, & their team at Revival Research have always gone above and beyond to recruit patients for the trial! One thing that stands out is their urgency when working with NOCD referrals while also being patient and understanding. On top of that, they are always looking through the NOCD portal to see if patients who were disqualified earlier may be eligible now. Thank you, Revival team, for your hard work - it does not go unnoticed!"

Deborah Price

biohaven pharmaceuticals

One thing that stands out is their urgency when working with NOCD referrals while also being patient and understanding.

A high level of patient engagement and adherence to study procedure compliance at site level.

SETTING INDUSTRY STANDARDS: SCRS BRIGHT IDEA AWARD WINNER

Award-winning Idea: AI-Powered Metrics in CTMS

Award: Bright Idea Award – SCRS Global Site Solutions Summit 2024

Team Lead: Nicole & 5-member Site Network Team

Overview

Revival Research Institute was honored with the prestigious Bright Idea Award at the SCRS Global Site Solutions Summit 2024 for pioneering the integration of AI-powered performance metrics within our Clinical Trial Management System (CTMS).

The Bright Idea

A transparent, data-driven "report card" that objectively reflects site performance, ensuring sponsors receive metrics over narratives. This tool challenges conventional evaluation approaches by making real-time performance visible and actionable.

Impact

- Recognized on stage at SCRS among global industry leaders
- Set a new industry benchmark for AI integration in clinical trial oversight
- Reinforced Revival's position as a thought leader in site innovation

ALZHEIMER'S RESEARCH — LEADING THE WAY IN ENROLLMENT & RETENTION

STUDIES: LAKI & AACM ELI LILLY ALZHEIMER'S DISEASE

KEY HIGHLIGHTS

- 828 subjects engaged for AACM
- Top 5 globally in randomization for AACM
- 334 screenings in just 3 days (Ann Arbor Art Fair)
- 289 LAKI pre-screenings
- 501 pre-screenings in 1 month (Eli Lilly LAKI)
- 20 randomizations from 827 screeners
- First site globally to screen a LAKI patient
- Maintained long-term engagement over a 5-year study

What Sets Us Apart

Revival demonstrated unmatched agility and community engagement. From mass screening events to retaining patients across long study durations, our site stands out as a high-performing, reliable partner in complex neurodegenerative research.

PFIZER FLU VACCINE TRIALS – CRUSHING ENROLLMENT GOALS

STUDY: PFIZER FLU VACCINE
ENROLLMENT GOAL MET: 150%
LEADS GENERATED:
50+ PER WEEK

Overview

Through a blend of local outreach and centralized campaigns, we surpassed flu vaccine enrollment targets significantly. Our proactive pipeline management enabled us to maintain a steady lead volume and drive faster enrollments.

Success Drivers

- Targeted lead generation efforts
- Multiple Flu studies successfully conducted and ongoing
- Data-driven recruitment strate

APNIMED – TOP ENROLLER IN NORTH AMERICA

STUDY: APNIMED OSA (OBSTRUCTIVE SLEEP APNEA)

PATIENTS ENROLLED: 286

ACHIEVEMENT: TOP ENROLLING SITE ACROSS THE UNITED STATES & CANADA 50+ PER WEEK

Overview

Revival played a critical role in the Apnimed OSA trial by contributing high-quality, high-volume enrollments ahead of schedule. Our site's performance was instrumental in driving study momentum across North America.

ALNYLAM KARDIA STUDIES — A GLOBAL POWERHOUSE IN HYPERTENSION RESEARCH

STUDIES: ALNYLAM KARDIA 2 & 3 HYPERTENSION

Achievements

- **Kardia 2:** Top 10 enroller globally
- **Kardia 3:** Ranked 6th in the world for randomizations

Impact

Our consistent, high-level enrollment helped accelerate timelines and validate global protocols in complex cardiovascular studies. We brought precision, speed, and scale to Kardia's multi-site initiatives.

ELI LILLY EZEF STUDY – DELIVERING RELIABLE DATA AT SCALE

STUDY: ELI LILLY EZEF – ATHEROSCLEROTIC CARDIOVASCULAR DISEASE (LP(A))
SCREENINGS: 379
RANDOMIZATIONS: 25

Overview

Revival's performance in the EZEF study reinforced its operational strength in managing high-volume studies with precision screening, rapid processing, and ethical integrity, ensuring dependable data flow to sponsors.

LEADING THE WAY IN FIRST PATIENT-IN: ELI LILLY DSAF STUDY

STUDY: ELI LILLY DSAF – HIDRADENITIS SUPPURATIVA

When timelines are tight and the stakes are high, Revival delivers. In the Eli Lilly 17P-MC-DSAF study, our site, led by Dr. Moiin and team, rose to the occasion by randomizing the first patient globally, a critical milestone that set the pace for the entire trial.

With operational precision and clinical readiness, the team didn't stop at one; they quickly followed up by randomizing four additional patients in just a few weeks, showcasing our ability to act fast without compromising quality.

OUR PERFORMANCE IN THE DSAF STUDY REFLECTS WHAT MAKES REVIVAL EXCEPTIONAL:

- Speed to action
- Strong site coordination
- Unmatched investigator commitment

We're proud to be recognized by the sponsor for our contributions and look forward to continuing this momentum in future studies

> **Dear Investigator and Study Team,**
>
> We are happy to announce that, on November 8th the first patient has been randomized in the 17P-MC-DSAF study.
>
> As of 07-Dec-2023, 5 patients have been randomized, and there are 3 in screening. Congratulations to Dr. Moiin and his team for randomizing the first study patient, and three extra ones!

THANK YOU

FOR BEING A PART OF OUR MISSION

To every team member, every partner, and every patient who has been a part of this journey, thank you. Your trust, dedication, and hard work have made this story possible. Together, we will continue to make strides in clinical research and patient care, redefining what is possible, one clinical trial at a time.

We look forward to continuing to make a positive impact in clinical research & patient care, together.

For more information

(248) 721-9539

info@rev-research.com